Sienna Gestion Has $5.55 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Sienna Gestion reduced its stake in Gilead Sciences, Inc. by 5.8% during the first quarter, leaving them with 50,969 shares valued at $5.55 million.
• Insider transactions include Johanna Mercier selling 3,000 shares and CEO Daniel O'Day selling 10,000 shares, indicating a decrease in their respective holdings.
• Gilead Sciences reported a quarterly earnings per share (EPS) of $2.01, exceeding analysts' expectations, along with a revenue of $7.08 billion.

Sienna Gestion lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,969 shares of the biopharmaceutical company's stock after selling 3,130 shares during the quarter. Sienna Gestion's holdings in Gilead Sciences were worth $5,551,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. E Fund Management Co. Ltd. lifted its stake in Gilead Sciences by 46.6% in the first quarter. E Fund Management Co. Ltd. now owns 46,594 shares of the biopharmaceutical company's stock valued at $5,221,000 after buying an additional 14,820 shares during the period. Financial Network Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 538.6% during the 1st quarter. Financial Network Wealth Advisors LLC now owns 364 shares of the biopharmaceutical company's stock valued at $41,000 after buying an additional 307 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its holdings in Gilead Sciences by 5.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 39,221 shares of the biopharmaceutical company's stock worth $4,395,000 after purchasing an additional 1,867 shares in the last quarter. S Bank Fund Management Ltd purchased a new stake in Gilead Sciences during the 1st quarter worth about $161,000. Finally, National Pension Service increased its stake in Gilead Sciences by 6.9% in the 1st quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company's stock worth $389,191,000 after acquiring an additional 223,171 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $0.65 during trading hours on Friday, reaching $118.37. 8,859,738 shares of the company traded hands, compared to its average volume of 6,512,909. The firm's 50-day moving average is $111.88 and its 200-day moving average is $108.42. The stock has a market cap of $146.87 billion, a P/E ratio of 15.29, a P/E/G ratio of 0.73 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $72.89 and a 1-year high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The firm had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter last year, the firm earned $2.01 earnings per share. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is presently 62.95%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares in the company, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company's stock, valued at $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,500 shares of company stock valued at $8,734,625. 0.27% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GILD. UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Morgan Stanley upped their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Royal Bank Of Canada increased their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Finally, Cantor Fitzgerald assumed coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $114.82.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.